Physiomics Plc (PYC.L) Research

Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.

Market snapshot

Symbol
PYC.L
Price
$0.53
Day change
0.00%
Market cap
$1.8M
P/E ratio
-3.09x
52-week range
0.253-0.8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • Polarean Imaging plc (POLX.L)
  • Roquefort Therapeutics plc (ROQ.L)
  • Theracryf Plc (TCF.L)
  • Trellus Health plc (TRLS.L)
  • ValiRx plc (VAL.L)

Open Physiomics Plc (PYC.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.